Reproducibility Passport · Co-Immunoprecipitation of the RAF-MEK Complex to Assess Disruption by the MEK Inhibitor Trametinib in BRAF-V600E A375 Melanoma Cells — Olto Discovery
Completeness score: 55 out of 100, grade C
C
55/100
Reproducibility Passport
Co-Immunoprecipitation of the RAF-MEK Complex to Assess Disruption by the MEK Inhibitor Trametinib in BRAF-V600E A375 Melanoma Cells
Grade C · DevelopingOncology
A deterministic, publicly-verifiable summary of how reproducible and transparent this protocol is, computed from open signals only and never from private lab data.
Reproducibility dimensions
Methodological rigor
100
7 of 7 reproducibility signals present.
Passed:
Experimental controlsControls are specified for valid comparison.
Passed:
ReplicationBiological/technical replicates are described.
Passed:
Sample size / powerSample size or power is justified.
Passed:
Statistical analysisA statistical analysis plan is included.
Passed:
How to strengthen this passport
Reference a recognized standard your method follows (e.g. ISO 17025, ASTM, USP, 21 CFR Part 11).
Add a references section citing the sources your method builds on.
Link the author ORCID iD for verifiable attribution.
Iterate and version the protocol — a revision history strengthens provenance.
Verifiable artifact
This passport is reproducible: anyone can recompute it from the public protocol. Cite it with the canonical URL below.
Co-Immunoprecipitation of the RAF-MEK Complex to Assess Disruption by the MEK Inhibitor Trametinib in BRAF-V600E A375 Melanoma Cells [Reproducibility Passport]. (2026). Olto Discovery. https://www.oltodiscovery.com/passport/co-immunoprecipitation-of-the-raf-mek-complex-to-assess-di-0e0352